Best-selling author Colleen Hoover, known for novels such as "It Ends With Us," revealed this week that she has been undergoing treatment for cancer, including successful surgery and nearly completed radiotherapy. The 46-year-old US writer shared the news in an Instagram post, featuring a selfie in a hospital gown, and further elaborated in a message to fans on Tuesday.
Hoover stated that her diagnosis occurred "a while ago," but she chose to keep it private until after learning of the surgery's success and the details of her subsequent treatment plan. She initially disclosed the information to her fan group, Colleen Hoover's CoHorts, on Facebook about a month prior, confirming that the cancer had been removed and that she was "okay."
In her Facebook post, Hoover explained that she had experienced recurring health issues throughout 2025. However, she prioritized the filming of the movie adaptation of "Reminders of Him" in Canada and delayed seeking medical attention at that time.
While Hoover has not specified the type of cancer she was diagnosed with, early detection and successful surgical removal are often critical factors in positive outcomes for many types of cancers, according to the American Cancer Society. Radiotherapy, also known as radiation therapy, is a common cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. It is often used after surgery to eliminate any remaining cancer cells.
The author's decision to delay seeking medical attention highlights a common challenge faced by many individuals, particularly women, who may prioritize work or family obligations over their own health. Experts emphasize the importance of regular check-ups and prompt medical evaluation of any unusual symptoms.
Hoover's latest novel, "Woman Down," her first since 2022, was released this week. Her openness about her health journey may encourage others to prioritize their well-being and seek timely medical care. Further updates on Hoover's health status are expected to be shared through her social media channels.
Discussion
Join the conversation
Be the first to comment